The efficacy of a peptide-nucleic acid solution (Reticulose) for the treatment of hepatitis A and hepatitis B--a preliminary controlled human clinical trial.
To complete this preliminary study 53 patients were chosen. All patients were screened, diagnosed for Hepatitis A or Hepatitis B and separated into treatment and control groups. All of the patients selected were in the early onset stage of their infection, and diagnosed for Hepatitis A or B by appropriate laboratory tests with special attention to Anti-HAV, IGM and HepB surface Antigen to carefully differentiate those with A from those with B. The treated patients received Reticulose for a 15 day period and the control patients received placebo injections of physiological saline. Reticulose patients with Hepatitis showed positive. 18 patients with Hepatitis B and 9 patients with Hepatitis A were treated with Reticulose, compared to 17 control patients with Hepatitis B and 9 control patients with Hepatitis A treated with placebo. Based upon laboratory findings of several parameters; Prothrombin times, Serum bilirubin, white blood cell (WBC count) and clinical observations; Reticulose treated patients appeared to show significant improvement. The bilirubin levels of 83% of patients with Hepatitis B, treated with Reticulose for 15 days were in normal range in 30 days. None of the control patients were within normal range after 30 days with placebo treatment. Of Hepatitis A patients treated with Reticulose, 100% showed normal bilirubin after 30 days. Of control patients with Hepatitis A, only 22% were in normal range after 30 days. The findings in this preliminary trial lead to the conclusion that Reticulose appears to significantly reduce the recovery time and return to normal for patients with an acute episode of Hepatitis A or B. Further study is indicated.